Cost-effectiveness analysis of pembrolizumab versus...

Lung Cancer 2019 / 01 Vol. 127

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Chouaid, Christos, Bensimon, Lionel, Clay, Emilie, Millier, Aurélie, Levy-Bachelot, Laurie, Huang, Min, Levy, Pierre
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
127
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/j.lungcan.2018.11.008
Date:
January, 2019
File:
PDF, 2.57 MB
english, 2019
Conversion to is in progress
Conversion to is failed